Table 3.
Immune responses of pregnant women living with HIV in the single-dose and two-single-doses groups
|
A/H1N1pdm09 |
A/H3N2 |
B/Yamagata |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Single-dose group (n=230) | Two-single-doses group (n=220) | p value | Single-dose group (n=230) | Two-single-doses group (n=220) | p value | Single-dose group (n=230) | Two-single-doses group (n=220) | p value | |
| HAI GMTs at baseline | 9·6 (8·5–10·9) | 9·5 (8·4–10·8) | 0·76 | 11·8 (10·5–13·3) | 12·5 (11·0–14·2) | 0·99 | 5·9 (5·6–6·2) | 5·9 (5·6–6·2) | 0·94 |
| HAI GMTs at 28–35 days after completion of full vaccine series*† | 39·5 (33·1–47·1) | 46·7 (39·7–54·9) | 0·17 | 37·8 (32·3–44·1) | 44·1 (37·5–51·9) | 0·18 | 13·0 (11·6–14·5) | 15·5 (13·9–17·3) | 0·029 |
| HAI antibody ≥1/40 at baseline | 33 (14%) | 31 (14%) | 0·94 | 34 (15%) | 51 (23%) | 0·023 | 4 (2%) | 2 (1%) | 0·59 |
| HAI antibody ≥1/40 at 28–35 days after completion of full vaccine series† | 142 (62%) | 148 (67%) | 0·22 | 131 (57%) | 145 (66%) | 0·051 | 46 (20%) | 54 (25%) | 0·25 |
| Seroconversion at 28–35 days after first vaccination† | 113 (49%) | 115 (52%) | 0·51 | 95 (41%) | 103 (47%) | 0·24 | 41 (18%) | 50 (23%) | 0·20 |
Data are n (%) and GMTs with 95% CI in parentheses. Only women who attended the visits within the protocol-defined time periods are included. GMTs=geometric means titres. HAI=hemagglutination inhibition antibody.
*
GMTs significantly higher than at baseline for all comparisons.
†
For single-dose group assessed at 28–35 days after first injection; for two-single-doses group assessed at 28–35 days after second injection.